- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07948772
A Study to Compare the Natural History of Ataxia Telangiectasia (AT) in Children to Healthy Comparators (INSPIRE AT)
INSPIRE AT: Longitudinal Study Comparing the Natural History of Ataxia Telangiectasia in Children to Healthy Comparators
The primary objective of this study is to assess the natural history of AT symptoms and disease progression over time in children aged 1 to 10 years old diagnosed with classic AT.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Insmed Medical Information
- Telefonnummer: 1-844-446-7633
- E-post: medicalinformation@insmed.com
Studieorter
-
-
California
-
Los Angeles, California, Förenta staterna, 90095
- Har inte rekryterat ännu
- USA004
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21287-0005
- Rekrytering
- USA002
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Rekrytering
- USA001
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030-3008
- Rekrytering
- USA003
-
-
-
-
-
Nottingham, Storbritannien, NG7 2UH
- Rekrytering
- GBR001
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Participants who meet all the inclusion criteria and none of the exclusion criteria will be eligible for inclusion in their respective cohort as appropriate.
Beskrivning
Inclusion Criteria for the AT Cohort:
- Diagnosis of classic AT based on investigator's assessment of clinical presentation and genotyping.
- If three years to 10 years (<11 years) old, the primary caregiver has self-reported to the site that the participant with AT can walk approximately 33 feet (10 meters) without support from a helper, and without the use of a walking aid.
- Provision of a valid study participant assent form, as applicable, together with a correctly signed and dated primary caregiver informed consent form.
Inclusion Criteria for the Healthy Comparator Cohort:
- Provision of a valid study participant assent form, as applicable, together with a correctly signed and dated primary caregiver consent form.
Exclusion Criteria for the AT Cohort:
- Participation in a clinical trial of a candidate therapeutic for AT, with last administration of a candidate therapeutic within 30 days or five half-lives (whichever is longer) preceding study baseline (start of data collection). For clarity, ongoing clinical trial participation that does not involve a therapeutic drug is acceptable. An exception to this exclusion is that up to approximately 20 participants receiving levacetylleucine (marketed as AQNEURSA®) in investigational trials, expanded access programs, or as a licensed drug are eligible.
- Previous treatment with a chemotherapeutic agent for cancer.
- Diagnosis of a condition other than AT that, in the opinion of the investigator, would compromise AT symptom measurement or current study participation.
Exclusion Criteria for the Healthy Comparator Cohort:
- Diagnosis of any form of AT.
- Previous treatment with a chemotherapeutic agent for cancer.
- Diagnosis of a condition that, in the opinion of the investigator, would compromise the measurement of movement by wearable devices to serve as healthy comparators to AT participants.
Note: Other protocol-defined inclusion/exclusion criteria may apply.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: CASE_CONTROL
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
|---|
|
AT Cohort
Participants with confirmed AT at screening visit will be enrolled and followed for 24 months. |
|
Healthy Comparator Cohort
Participants without diagnosis of AT at screening visit will be enrolled and followed for 24 months. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
AT Cohort: Change From Baseline in AT Neurological Examination Scale Toolkit (A-TNEST) Score
Tidsram: Baseline up to Month 24
|
Baseline up to Month 24
|
|
AT Cohort: Change From Baseline in International Cooperative Ataxia Rating Scale (ICARS) Score
Tidsram: Baseline up to Month 24
|
Baseline up to Month 24
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change From Baseline in Height
Tidsram: Baseline up to Month 24
|
Baseline up to Month 24
|
|
|
Change From Baseline in Weight
Tidsram: Baseline up to Month 24
|
Baseline up to Month 24
|
|
|
Percentage of Participants Achieving Pre-defined Developmental Goals as Assessed by Denver Developmental Screening Test (DDST-II)
Tidsram: Up to Month 24
|
Up to Month 24
|
|
|
AT Cohort: Change From Baseline in Pediatric Quality of Life Inventory (Peds QL) Score Measured by the Pediatric Quality of Life Inventory
Tidsram: Baseline up to Month 24
|
Baseline up to Month 24
|
|
|
Change From Baseline in Motor Activity Assessed by Wearable Device
Tidsram: Baseline up to Month 24
|
A wearable accelerometer will capture participant's movements during their everyday activities at home. These data will be processed using specific algorithms to generate measurements that include total sedentary time and time spent in light, moderate and vigorous activity. |
Baseline up to Month 24
|
|
Change From Baseline in Arm Function Assessed by Hevelius Test
Tidsram: Baseline up to Month 24
|
Baseline up to Month 24
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Study Director, Insmed Incorporated
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Primära immunbristsjukdomar
- Neurologiska manifestationer
- Hjärnsjukdomar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Kärlsjukdomar
- Hjärt-kärlsjukdomar
- Genetiska sjukdomar, medfödda
- Metaboliska sjukdomar
- Immunsystemets sjukdomar
- Immunologiska bristsyndrom
- Neurokutana syndrom
- Dyskinesier
- DNA-reparation-briststörningar
- Cerebellära sjukdomar
- Cerebellär ataxi
- Spinocerebellär ataxi
- Ataxi
- Telangiektas
- Medfödda, ärftliga och neonatala sjukdomar och abnormiteter
- Närings- och metabola sjukdomar
- Ataxi Telangiectasia
Andra studie-ID-nummer
- INS NHS AT001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .